#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Nodal marginal zone B-cell lymphoma Gestational trophoblastic tumour Colon cancer Adenocarcinoma pancreas Mantle cell lymphoma stage II Congenital generalised lipodystrophy Cholestatic pruritus Immunodeficiency common variable Myelofibrosis Mucopolysaccharidosis III Hereditary motor and sensory neuropathy Arterial disorder Liver abscess Choroid melanoma Cardiac amyloidosis More trials…

    Learn about Rare Diseases

    Congenital generalised lipodystrophy Cystic fibrosis – Basic Information Langerhans’ cell histiocytosis – Diagnostics Loeys-Dietz syndrome – Treatment Propionic acidaemia – Basic Information Mantle cell lymphoma stage II – Diagnostics Langerhans’ cell histiocytosis Mantle cell lymphoma stage III – Treatment Tuberous sclerosis complex – Diagnostics Gaucher’s disease type III – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Methylprednisolone Lonvoguran Camphor NVG-2089 Tranexamic Acid ALPROSTADIL F44/10 Tinlarebant Propafenone Hydrochloride Bi 1819479 Treg02 10-1074-Ls Cytisinicline Cx-039776 Azd5462 Eprosartan Mesilate Naxitamab Specific Nucleic Acid Sna-Veru Benzylpenicillin Elezanumab More therapies…

    Learn about Your Condition

    Viral myocarditis Haemodialysis Oesophageal food impaction B-cell lymphoma refractory Neoplasm malignant Pemphigoid Urticaria Carcinoid syndrome Chorea Autoimmune uveitis Juvenile idiopathic arthritis Atrial flutter Abdominal wall pain Multiple system atrophy Anal cancer stage II More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Krankenhaus Nordwest GmbH

Krankenhaus Nordwest GmbH

Steinbacher Hohl 2-26, Praunheim, Frankfurt, 60488, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Durvalumab, Cisplatin, Carboplatin, and Etoposide for Patients with Extensive Stage Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Durvalumab
    Germany

  • A study of daraxonrasib (RMC-6236) compared to observation in patients with resected pancreatic cancer following chemotherapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Ductal adenocarcinoma of pancreas
    Investigated Drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    France Germany Italy Spain

  • A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Calcium Folinate
    • Capecitabine
    Austria Belgium Czechia France Germany Italy +5

  • Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Adagrasib
    • Pembrolizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +13

  • Randomized trial of irinotecan drug combination versus standard therapy as first-line treatment in patients with locally advanced or metastatic small bowel adenocarcinoma

    Not yet recruiting

    4 1 1 1
    Investigated Diseases:
    • Small intestine adenocarcinoma
    Investigated Drugs:
    • Calcium Folinate
    • Fluorouracil
    • Irinotecan Hydrochloride Trihydrate
    Germany

  • First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

    Not yet recruiting

    3 1
    Investigated Drugs:
    • (2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
    Austria Belgium Czechia Denmark France Germany +6

  • Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Ramucirumab
    • Tislelizumab
    • Calcium Folinate
    Germany Italy Spain

  • Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

    Not yet recruiting

    4 1 1
    Investigated Drugs:
    • Efgartigimod Alfa
    Austria Germany

  • DB-1311 in Combination with BNT327 or DB-1305 for Patients with Advanced or Metastatic Solid Tumors

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Cervix carcinoma
    • Hepatocellular carcinoma
    • Malignant melanoma
    Investigated Drugs:
    • BNT327
    • HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TROP2 CONJUGATED TO N-((7S,15S)-7-BENZYL-17-(((1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL-10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12H-BENZO[DE]PYRANO[3′,4′:6,7] INDOLIZINO[1,2-B]QUINOLIN-1-YL)AMINO)-15-METHYL-2,5,8,11,17-PENTAOXO-14-OXA-3,6,9,12-TETRAAZAHEPTADECYL)-6-(2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-1-YL)HEXANAMIDE
    France Germany Italy Poland Spain

  • Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Zipalertinib
    • Carboplatin
    • Cisplatin
    Belgium France Germany Greece Italy The Netherlands +3
Previous Page
1 … 5 6 7 8 9 … 14
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!